Our company was co-founded by leading pioneers in precision oncology and RAS targeting—to create novel therapies and combination regimens designed to comprehensively silence the RAS/MAPK pathway for the treatment of cancer.
Our leadership team and employees have broad and deep experience in company building and in oncology, including advancing therapeutic candidates from discovery research to clinical development, regulatory approval, and commercialization.
Senior Vice President of Pharmaceutical Development and Operations
Chairman, CEO and Co-founder
Jonathan is Chairman and CEO of Erasca, which he co-founded in July 2018 with a mission to erase cancer. He is a physician-turned-venturepreneur at City Hill and ARCH Venture who founds, funds and leads mission-driven for-profit and non-profit ventures. He has served as Chairman and/or CEO and founding investor of six biotechnology companies that have collectively achieved global regulatory approval and launch of seven therapeutic products in oncology, immunology and drug delivery, benefitting thousands of patients worldwide, while generating approximately $10 billion of shareholder value. Jonathan has pioneered transformative advancements in drug delivery and precision oncology.
In drug delivery, he designed and executed landmark deals for Halozyme’s ENHANZE® drug delivery technology with Roche/Genentech and Baxter that formed the foundational business model and template for the company’s ten global alliances and five approved ENHANZE products that have enabled Halozyme to turn EBITDA positive and guide to $1 billion in royalty revenue in 2027. In precision oncology, Jonathan led Ignyta’s trailblazing pursuit of a global tissue agnostic label to transform cancer treatment with ROZLYTREK® (entrectinib) that, in the process of securing global regulatory approvals, became the first drug in biopharmaceutical history to achieve the unprecedented triple crown of breakthrough designations with BTD (FDA), PRIME (EMA) and Sakigake (PMDA). He led the strategic process that successfully resulted in the acquisition of Ignyta to become a key personalized healthcare pillar for Roche/Genentech, the leading precision oncology company in the world. He is continuing to pursue new frontiers of precision oncology at Erasca.
Chair of R&D, SAB Member and Board Director
Mike is the Chair of R&D, SAB Member and Board Director at Erasca. In these roles, he will help advance Erasca’s drug discovery portfolio by providing strategic input on portfolio optimization and offering in-depth scientific assessments of Erasca’s R&D activities.
Mike is a pioneer drug discoverer and biotech leader. As one of the original fifteen employees at Agouron, a biotech based in San Diego, he built a team that developed protein-structure based design, a novel approach to drug discovery that is utilized globally by drug discovery teams today. In 1997, the Agouron team launched Viracept®, an HIV protease inhibitor that achieved the highest first year launch sales of any biotech product at the time. His leadership at Agouron resulted in the discovery of multiple currently marketed anti-cancer agents, including Xalkori® and Inlyta®, a drug that won the American Chemical Society’s Heroes of Chemistry Award in 2018.
In 2005, Mike was recruited to Genentech to expand the organization’s drug discovery capabilities to include small molecules. Focused on agility and pioneering science, Mike built a team-based organization that today produces more than 40% of Genentech’s development portfolio, including the marketed anti-cancer agents Erivedge® and Cotellic®.
In 2015, Mike was appointed Executive Vice President and Head of Genentech’s Research and Early Development (gRED) and a member of the Roche Corporate Executive Committee. In this role, he was responsible for all aspects of gRED innovation, drug discovery and development. Mike also focused on building a team-based culture empowered to clear the path to patients. Under his leadership, gRED teams discovered and developed successful medicines that include Venclexta® with AbbVie, the first BCL-2 inhibitor, and Polivy™, an antibody drug conjugate for the treatment of DLBCL. Pioneering molecules in clinical development include mosunetuzumab, a bispecific antibody targeting CD20, and GDC-9545, a next-generation estrogen receptor degrader. Mike retired from Genentech in July 2020, leaving a diversity of drug platform types that includes personalized therapeutic vaccines and cellular therapies.
Mike holds a B.S. in Chemistry from the University of California, Los Angeles, and a Ph.D. in synthetic organic chemistry from the California Institute of Technology, and was an American Cancer Society postdoctoral fellow at Columbia University.
Chief Financial Officer and Chief Business Officer
David is Chief Financial Officer and Chief Business Officer of Erasca, where he leads finance, investor relations, corporate and business development, and other functions. Bringing deep experience in strategy, finance, business development, and operations, he joined the company in 2019 as Chief Business Officer with oversight of its corporate and business development efforts and became Chief Financial Officer in 2020. Prior to Erasca, he was a Principal at Versant Ventures, where he held a dual investing/operating role, helping lead investment opportunities across multiple therapeutic areas. Operationally, he was intimately involved in advancing several Versant portfolio companies through company formation, fundraising, business development, and clinical and regulatory activities. David joined Versant from Alcon, where, as Chief of Staff to the CEO, he worked alongside the executive leadership team to develop and implement high priority corporate initiatives to accelerate growth and innovation. Prior to Alcon, David was an Engagement Manager at McKinsey, leading multiple teams serving pharmaceutical and medical device clients, across sales and marketing, R&D, finance, and other functions. Previously, David worked at SR One, the venture capital arm of GSK. He also worked at Amgen in commercial operations and at Morgan Stanley in investment banking.
David holds an M.D. from the University of Pennsylvania, where he was a Gamble Scholar and President of the medical student body, and an MBA from the Wharton School. He earned an MPhil from Oxford University as a Marshall Scholar, as well as undergraduate degrees in biology and business from the University of Southern California, where he graduated as the University Valedictorian.
Chief Operating Officer
As Chief Operating Officer, Nik brings over 20 years of experience in drug development to Erasca, where he works with our talented scientists and staff in the pharmaceutical development and operations (CMC), information technology, operations and facilities, quality assurance, and portfolio and program leadership groups. Nik has worked at several major pharmaceutical companies, including GlaxoSmithKline, Pfizer and Genentech, spanning technical development from discovery to new drug application (NDA) filings (Wellbutrin®, Erivedge® and Cotellic®) and transfer to commercial groups. Upon joining Genentech in 2006, he helped build the small molecule drug development organization and drive the significant expansion of technical and drug manufacturing capabilities. During his Genentech tenure, Nik served on multiple governance committees, was a technical development team leader, and represented Genentech on the board of directors for the Allotrope Foundation. Prior to joining Erasca, he was the Co-founder and President of MindScienceConnection, Inc., a strategy and leadership development company that focused on partnering with biopharmaceutical companies to navigate the unique challenges of building and maintaining thriving research cultures while developing the scientific leaders of the future.
Nik earned his M.S. and Ph.D. in pharmaceutical chemistry from the University of Kansas and his B.Sc. in chemical and pharmaceutical sciences from the University of Sunderland.
General Counsel
Ebun is Erasca’s General Counsel and Corporate Secretary. He has represented publicly traded life science companies for over 20 years and has served as an in-house counsel since 2005. During his career, Ebun has been General Counsel or Assistant General Counsel at early stage biopharmaceutical companies and a medical device company, including Imbria Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals and Alphatec Spine. At each company, he provided legal support with respect to product development, business development, corporate finance and public company reporting. Prior to his in-house positions, he was a corporate associate at the New York office of the law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo.
Ebun earned a B.A. in economics from the University of Pennsylvania and a J.D. from New York University School of Law.
Chief Regulatory Affairs Officer
Chandra is Erasca’s Chief Regulatory Affairs Officer, bringing 20 years of global drug development experience, ranging from pre-investigational new drug activities through new drug application (NDA) submission and post-approval. Her career has focused on oncology and has included drug/diagnostic development and novel trial designs and endpoints. She joined Erasca from G1 Therapeutics, where she was Vice President of Regulatory Affairs and led health authority negotiations resulting in US Food and Drug Administration (FDA) breakthrough therapy designation and NDA approval for Cosela™. Chandra previously served as Senior Vice President, Global Regulatory Affairs and Head of Quality at Sierra Oncology and Vice President of Global Regulatory Affairs at Endocyte. Earlier in her career, she held roles of increasing responsibility at Genentech, including as regulatory lead for Avastin®, and previously was at Avi BioPharma.
Chandra has an M.S. in regulatory affairs from San Diego State University and a B.S. in organizational behavior from the University of San Francisco.
Chief Medical Officer
Shannon brings over 20 years of experience in the life sciences with a focus in oncology. She joined Erasca from Istari Oncology, where she was Vice President, Head of Clinical Development, and a member of the executive committee. Prior to joining Istari, she was Vice President of Clinical Development at G1 Therapeutics where she led the development of Cosela™, achieving breakthrough therapy designation as well as a successful NDA. As a senior director at MedImmune, the global biologics research and development arm of AstraZeneca, she supported the successful biologics license application (BLA) for Imfinzi® and led the development of multiple early phase immuno-oncology assets. At GlaxoSmithKline, she held roles of increasing responsibility where her efforts focused on the early phase development of small molecule inhibitors of AKT, PI3K, and MEK, including the approved MEK inhibitor Mekinist®. During her time at GlaxoSmithKline and MedImmune, Shannon maintained an adjunct appointment at the University of North Carolina where her practice focused on the clinical care of patients with breast and gastrointestinal cancers.
Shannon completed her internal medicine residency and oncology fellowship at the University of North Carolina, earned an M.D. and Ph.D. in molecular virology from Case Western Reserve University, and holds a B.S. in biological sciences from Stanford University.
Chief People Officer
Lisa brings more than 20 years of experience as a strategic leadership consultant, with expertise in organizational development, culture, and talent management. She has partnered with diverse leaders and teams in the life sciences industries of biotechnology, pharmaceuticals, and contract research organizations as well as across a multitude of other industries including hospitals, technology, energy, financial services, telecommunications, and law enforcement, and she has served as a volunteer coach to former U.S. Navy SEALs. Prior to joining Erasca, she was founder and president of Inspire True Leadership, an organizational advisory company focused on enabling business growth through leadership excellence and a strong people agenda. She also was a director at Mellon Financial and a director in the global human resources practice of PricewaterhouseCoopers.
Lisa holds Ph.D. and M.S. degrees in industrial/organizational psychology from Tulane University and a B.A. in psychology from the University of California, Santa Barbara.
Senior Vice President of Finance
Brian joined Erasca as Senior Vice president of Finance. With more than 25 years of industry experience, he has provided executive level financial expertise to both public and private biotechnology companies, including Turning Point Therapeutics (TPTX), Cleave Biosciences and Phenomix Corporation. Prior to Erasca, Brian most recently served as Senior Vice President of Finance and Administration at TPTX, where he led all corporate accounting, finance and planning activities. He played a key role in TPTX’s growth from a small private company into a multibillion-dollar public company and helped complete five financings with combined proceeds in excess of $1.3 billion, including a $191 million initial public offering in April 2019.
Brian earned his B.S. and M.S. degrees from San Diego State University and is an active certified public accountant in the state of California.
Senior Vice President of Early Clinical Development
Les serves as Senior Vice President of Early Clinical Development of Erasca, bringing more than 20 years of experience as a scientifically driven oncology drug developer in early phase clinical development and translational medicine. Les joined Erasca from Neon Therapeutics, where he led the clinical development of the personalized neoantigen vaccine program. He also led the clinical development of their shared neoantigen vaccine program resulting in the recent filing of the IND for this program. Prior to this, he served as the Program Team Leader of IPI-549, a PI3K-gamma inhibitor, at Infinity Pharmaceuticals. At Infinity, Les was responsible for the strategic and operational aspects of the molecule including the first-in-human study, IND filing and development of the overall clinical strategy. He began his career at Eli Lilly and Company in their early phase Oncology drug development group where he was the clinical lead on multiple programs, responsible for Phase I and II development. Les worked closely with the pre-clinical development teams to optimize the characteristics of the drug development candidates with a focus on clinically relevant biomarkers.
Les earned his Ph.D. in Medical Biophysics from the University of Toronto.
Vice President of Business Development
Combining over a decade of experience in business development with a strong science background, Rachel is Erasca’s Vice President of Business Development. She joined Erasca from GW Pharmaceuticals where she was responsible for developing the company’s external innovation strategy and leading its partnering activities from opportunity identification through agreement execution. Prior to GW, Rachel held similar roles at Synthetic Genomics, Egalet Corporation and Inovio Pharmaceuticals. In these roles she negotiated buy-side and sell-side R&D deals, led cross-functional teams in developing and implementing therapeutic area strategy and established key commercial partnerships. Rachel began her career at Merck, where she held roles of increasing responsibility within project and portfolio management, marketing and business development.
Rachel earned a Ph.D. in molecular biology from the University of Cincinnati, an MBA from the Wharton School and a B.A. from the University of Hawai’i at Manoa.
Vice President of Portfolio, Program, and Alliance Management
Tim joins Erasca with over 20 years of providing effective project and program management, portfolio prioritization and planning, and alliance management in the life sciences. Tim has a diverse career spanning academic research, clinical trial program management, project management, and as an entrepreneur. He has worked for or served as a consultant for a wide gamut of large and small pharmaceutical, biotechnology, medical device, and diagnostics companies. Most recently, Tim was Vice President of Program Management at Nektar Therapeutics where he served as the global program management lead for the bempegaldesleukin (NKTR-214) program, an immuno-oncology therapy of recombinant human interleukin-2 for multiple solid tumors. Tim brings a deep knowledge of our business, leadership to drive programs in a complex multidisciplinary environment, a passion for our science, and a keen sense of how to navigate the inevitable challenges faced by drug development teams.
Tim holds a Ph.D. in biochemistry from Harvard University (thesis research on PI3K/mTOR and Ras/Raf/MEK/MAPK), an M.S. in medicine from Harvard, and a B.S. in biochemistry from the University of Illinois. Tim also earned an MBA from the Wharton School at the University of Pennsylvania. He is a certified project management professional (PMP).
Vice President of Clinical Operations
Amy joins Erasca with more than 20 years of biopharmaceutical industry experience and nine years of academic research. Her work in the industry has run the spectrum from large companies such as Pfizer to medium and small companies such as CancerVax, FibroGen, and Medivation. In positions ranging from Clinical Research Associate to Vice President of Clinical Operations, she has worked across all clinical phases with an emphasis in oncology. She joins Erasca from Oncternal Therapeutics where she served as Vice President of Clinical Pperations. Her career highlights include being part of the successful NDA for Sutent® as well as being the clinical operations lead on the Talzenna® NDA team. Amy has expertise in planning and execution of clinical studies, clinical budgeting, process improvement, vendor partnerships, and oversight. Prior to joining industry, Amy worked at University of California, San Diego (UCSD) and Stanford Medical Center as a study coordinator.
Amy holds a master of public health in epidemiology from San Diego State University and B.A. in political science and psychology from UCSD.
Senior Vice President of Research
Robert is Erasca’s SVP of Research, having previously served as Erasca’s Vice President of Biology since helping launch the company in July 2018. Bringing over 20 years of experience and education in computational biology, he has deep biology, bioinformatics, and drug development experience. Prior to Erasca, Robert led the computational biology group at Ignyta, where he worked since the company’s inception in 2011 until its acquisition by Roche in 2018. He contributed to the successful development of lead drug candidate entrectinib by developing a patient selection strategy. He also led biomarker development for other preclinical and clinical candidates and developed a novel prototype blood-based next generation sequencing (NGS) assay for detecting autoimmune diseases. Before working at Ignyta, he was a scientist at Illumina, where he helped develop new products and investigate product quality via NGS data analysis.
Robert earned his Ph.D. in biochemistry at the University of California, San Diego.
Vice President of Chemistry
Jean-Michel is Erasca’s Vice President of Chemistry and brings more than 25 years of experience in drug discovery and development to help fuel the company’s mission of erasing cancer. At Erasca, he is leading a talented group of medicinal, computational, development and analytical scientists dedicated to discovering and advancing new medicines to treat patients with cancer. Jean-Michel joined Erasca from Ignyta, where he led the chemistry department managing all of Ignyta’s drug substance GMP production as well as early stage internal drug discovery programs. During his time at Ignyta, Jean-Michel accumulated a strong knowledge in drug discovery, GMP production, IND and NDA filings. Before working at Ignyta, he held positions of increasing responsibilities at several companies, including Ardea Biosciences, Merck Research Laboratories and SIBIA neurosciences. Jean-Michel has co-authored more than 30 peer-reviewed publications and is an inventor on more than 50 U.S. patents.
Jean-Michel earned his Ph.D. in Synthetic Organic Chemistry from the University Louis Pasteur, Strasbourg, France and was a postdoctoral fellow at Colorado State University.
Senior Vice President of Pharmaceutical Development and Operations
Minli is Erasca’s Senior Vice President of Pharmaceutical Development and Operations bringing more than 20 years of experience in drug development from discovery candidate selection through registration and launch. Prior to Erasca, she was one of the first 20 employees at Myovant Sciences, serving as Vice President of Pharmaceutical Operations and Development, where she built the CMC organization and oversaw the CMC activities that helped support the successful development and approval of Orgovyx® and the combination product, Myfembree®, for multiple indications. Previously, Minli was Head of Small Molecule Technical Operations at Medivation, and her team’s work enabled the registration and approval of Talzenna®. She also built and led the small molecule pharmaceutics team at Genentech, supporting the small molecule research and development projects, including Erivedge® and Cotellic®. She also worked at Bristol Myers Squibb and DuPont Merck in roles of increasing responsibility.
Minli has a Ph.D. in pharmaceutical chemistry and a B.S. in chemistry, both from the University of Kansas.
Senior Vice President of Clinical Pharmacology
Dawei serves as Erasca’s Senior Vice President of Clinical Pharmacology, bringing over 20 years of experience in drug discovery and development. He joined Erasca from Turning Point Therapeutics (TPTX), where he was Vice President of Clinical Pharmacology and a member of the leadership team. He was responsible for overall strategy and execution of clinical pharmacology plans to support the pipeline at TPTX, where he helped advance repotrectinib into a registrational trial and achieve FDA breakthrough therapy designation for the treatment of patients with TKI-naïve ROS1-positive metastatic non-small cell lung cancer. Prior to TPTX, Dawei worked at Pfizer for 17 years where he held roles of increasing responsibility, most recently as Senior Director of Clinical Pharmacology in the Early Oncology Development and Clinical Research (EODCR) organization. During his tenure at Pfizer, he worked on numerous investigational drugs across small molecules, large molecules, antibody drug conjugates and bispecific antibodies. He contributed to the discovery and development of three marketed medicines, including Eliquis®, Inspra® and Ibrance®. Earlier in his career, he worked for nine years in clinical pharmacokinetics and pharmacodynamics of antimicrobial agents at the Center for Anti-infective Research and Development at Hartford Hospital.
Dawei earned his Ph.D. in pharmaceutical sciences from the University of Connecticut and his B.S. in pharmaceutical sciences from Peking University Health Science Center.
Chairman, CEO and Co-founder
Jonathan is Chairman and CEO of Erasca, which he co-founded in July 2018 with a mission to erase cancer. He is a physician-turned-venturepreneur at City Hill and ARCH Venture who founds, funds and leads mission-driven for-profit and non-profit ventures. He has served as Chairman and/or CEO and founding investor of six biotechnology companies that have collectively achieved global regulatory approval and launch of seven therapeutic products in oncology, immunology and drug delivery, benefitting thousands of patients worldwide, while generating approximately $10 billion of shareholder value. Jonathan has pioneered transformative advancements in drug delivery and precision oncology.
In drug delivery, he designed and executed landmark deals for Halozyme’s ENHANZE® drug delivery technology with Roche/Genentech and Baxter that formed the foundational business model and template for the company’s ten global alliances and five approved ENHANZE products that have enabled Halozyme to turn EBITDA positive and guide to $1 billion in royalty revenue in 2027. In precision oncology, Jonathan led Ignyta’s trailblazing pursuit of a global tissue agnostic label to transform cancer treatment with ROZLYTREK® (entrectinib) that, in the process of securing global regulatory approvals, became the first drug in biopharmaceutical history to achieve the unprecedented triple crown of breakthrough designations with BTD (FDA), PRIME (EMA) and Sakigake (PMDA). He led the strategic process that successfully resulted in the acquisition of Ignyta to become a key personalized healthcare pillar for Roche/Genentech, the leading precision oncology company in the world. He is continuing to pursue new frontiers of precision oncology at Erasca.
Jim brings more than three decades of drug discovery, research and development at major pharmaceutical companies and continues to advise life science companies on optimizing efficiency and effectiveness of drug discovery and preclinical development. Jim currently serves as Chairman of Deciphera Pharmaceuticals, member of the Board of Directors of three privately financed biotechnology companies, and a Senior Advisor to Frazier Healthcare Partners. He previously served as a board member for Ignyta, Inc. and Cadent Therapeutics. During his industry career, Jim most recently held the role of Senior Vice President, Worldwide Drug Discovery Research for Pfizer Global Research & Development, where he was responsible for more than 3,000 scientists at seven Pfizer sites in the U.S., U.K., and Japan. Under his leadership, Pfizer’s scientists and collaborators produced an industry-leading number of drug development candidates in 11 therapeutic areas. Prior to joining Pfizer, Jim held positions of increasing responsibility in Chemistry and Drug Discovery at Parke-Davis. Jim has been involved with the discovery and development of both drugs that have been approved by the FDA, including Lipitor®, Lyrica®, and Ibrance®, and drug candidates currently in clinical development. Earlier in his career, Jim spent six years in the Chemistry Department at Schering-Plough as a Principal Scientist. Jim has served in numerous officer positions in the American Chemical Society Division of Medicinal Chemistry and was Vice Chairman and Chairman of the Gordon Conference on Medicinal Chemistry, Co-Chair of a Keystone Conference, Adjunct Professor of Medicinal Chemistry at the University of Michigan and Editor-in-Chief of the ACS Annual Reports in Medicinal Chemistry. He was an NIH Postdoctoral Fellow at University of Michigan and The Squibb Institute for Medical Research.
Jim holds a B.S. in chemistry from Bates College and received a Ph.D. in Organic Chemistry from the University of New Hampshire.
Alex is the Chief Operating Officer (COO) and Chief Financial Officer (CFO) of Epirium Bio. Prior to joining Epirium, Alex was founder, CEO and Portfolio Manager of Reneo Capital Management LP. A successful healthcare investor and executive, Alex brings more than 20 years of experience shaping and advising biopharmaceutical companies. Prior to forming Reneo, he served in roles including CFO of Sophiris Bio and Vice President of Finance of Amylin Pharmaceuticals. Previously, he served as a board member for Ignyta; and he ran Casdin Advisors LLC, providing strategic advice to life science companies, including Amylin. Before founding Casdin Advisors, Alex was CEO and Portfolio Manager of Cooper Hill Partners LLC, a healthcare investment fund, and before that, as Portfolio Manager of Pequot Capital Management’s healthcare fund. Earlier, Alex worked at the Dreyfus Corporation as a Senior Managing Analyst covering pharmaceuticals, biotechnology and medical devices. He also served as a Legislative Assistant to Congressman Robert J. Mrazek (D-NY) and then as Legislative Affairs Specialist for Patton Boggs LLP in Washington, D.C. He currently serves as on the Advisory Board of Luna DNA. He also is a board member, treasurer and executive committee member of the Conquer Cancer foundation of the American Society of Clinical Oncology, and a member of Brown University’s President’s Leadership Council. He also serves on the Advisory Board of the Hassenfeld Children’s Center for Pediatric Oncology and Blood Disorders at NYU Langone Medical Center.
Alex holds an A.B. in Political Science from Brown University and an MBA, Beta Gamma Sigma, from Columbia Business School.
Bihua is the founder of Cormorant Asset Management, LP (“Cormorant”), an investment firm focused on innovative biotechnology, medical technology and life science companies with assets under management of over $3 billion. Bihua manages Cormorant’s public fund as well as its private funds. Prior to founding Cormorant, she managed a separately managed account focused on the healthcare sector as a sub-adviser to a large, multi-strategy hedge fund based in New York.
Bihua obtained an MBA from the Wharton School and an M.S. in molecular biology from the Graduate School of Medical Sciences at Cornell Medical College. She also holds a B.S. in genetics and genetic engineering from Fudan University, Shanghai, China.
Julie is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and in the filings of Investigational New Drug (IND) applications, Biologics License Applications (BLA) and Special Protocol Assessments (SPA). Julie recently served as interim CEO at Arch Oncology. Previously, she served as Senior Vice President, Chief Medical Officer, and Head of Development at IDEAYA Biosciences, an oncology company. Prior to her role at IDEAYA, she held the positions of Vice President and Head of U.S. Medical at Bristol-Myers Squibb, where she oversaw medical & health economic and outcomes research activities in support of the oncology, immuno-oncology, specialty and cardiovascular marketed portfolios; Executive Vice President and Chief Medical Officer at Five Prime Therapeutics; and Vice President of Clinical Development at Clovis Oncology. Julie began her industry career at Genentech, most recently as Group Medical Director, Global Clinical Development. She also serves on the boards of directors of IGM Biosciences, Inc., and SpringWorks Therapeutics, Inc., both publicly traded biotechnology companies, as well as Accent Therapeutics, a privately held biotechnology company.
Julie completed her medical and hematology-oncology training at the University of California, San Francisco, where she then served on faculty from 1993 to 2003, and was Board-certified in hematology and internal medicine. She received her M.D. from Case Western Reserve University School of Medicine and a B.S. from Duke University.
Val is Principal and Advisor at Start Pharma Consulting. She brings to Erasca a proven track record of more than 30 years in the leadership, design and development of a diverse range of drug products in human health. Val has delivered projects from early research through development, manufacture and registration to commercial launch at both biotech and large pharmaceutical companies. Val furthered the delivery of more than 15 global registrations and new product launches across diverse therapeutic areas, including oncology, pediatric medicines, anti-infectives and ophthalmology. Following the acquisition of Ignyta by Roche, Val served as Site Head for Ignyta, leading the seamless transition of assets and operations, and accelerated simultaneous NDA, MAA and JNDA filings for entrectinib, the lead oncology asset. Val also served as Senior Vice President of Chemistry, Manufacturing and Controls for Ignyta, providing strategic direction, tactical oversight and technical expertise in Process Chemistry, Analytical Development, Formulation Development, Manufacturing and Supply Chain Management. Prior to Ignyta, she served as Vice President of Product Differentiation, Pharmaceutical Sciences for Worldwide Research and Development at Pfizer. In this capacity, she developed and implemented cross-functional (research, medicinal chemistry, drug metabolism, clinical pharmacology and pharmaceutical sciences) strategies for the design and progression of differentiated molecules and drug products. Val led and implemented the adoption of design thinking, rapid innovation and prototyping best and next practices to address cross-disciplinary scientific and business challenges. She is also a member of the community of practice and thought partner for Smallify, an innovation capacity-building firm. In addition to her skills and expertise in pharmaceutical sciences, Val combines her knowledge of leadership, science and business systems required for successful drug development from research to market.
Val holds a Bachelor of Pharmacy from the University of London, U.K., and received a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham, U.K.
Jean brings over 20 years of experience in the biotechnology industry, specializing in legal business leadership, including corporate governance, business transactions, intellectual property, and compliance. She currently serves as the chief legal officer of Seagen Inc., a global, multi-product, oncology focused biotechnology company. Previously, she was Vice President and General Counsel at Halozyme Therapeutics and Chief Legal Officer at Durect Corporation. Earlier in her career, Jean practiced law in the areas of intellectual property litigation and technology licensing at various law firms. She serves as a director on the board of Connect Biopharma Holdings, Ltd., a publicly traded biotechnology company focused on inflammatory diseases.
Jean received her J.D. from Columbia University, her M.S. in biology from Stanford University, and her B.S. in cellular and molecular biology from the University of Michigan.
Pratik is Chief Medical Officer of ORIC Pharmaceuticals, which is discovering and developing therapies to overcome resistance in cancer. Prior to joining ORIC in September 2018, Pratik was Chief Medical Officer at Ignyta until its acquisition by Roche in February 2018. While at Ignyta, he led clinical and nonclinical development, as well as regulatory strategy for Ignyta’s portfolio of precision medicines in oncology, including entrectinib, a novel CNS-penetrant TRK and ROS1 inhibitor. Pratik’s background encompasses broad scientific and management experience in clinical development with a deep understanding of oncology. He served as Chief Medical Officer at Fate Therapeutics, where he led the clinical development of novel stem cell therapies for the treatment of hematologic malignancies and other rare diseases, and was involved in leadership positions for the development of multiple innovative marketed cancer therapies, including Treanda (bendamustine), Zevalin (ibritumomab tiuxtetan), and Rituxan (rituximab). Prior to joining industry, Pratik held academic and clinical positions at Harvard Medical School and Massachusetts General Hospital, where he was a member of the bone marrow transplant unit. He completed an internship and residency training in internal medicine at Massachusetts General Hospital and his oncology fellowship at the Dana Farber-Partners combined program.
Pratik holds a B.S. from Yale University, an M.D. from Harvard Medical School, and an M.S. in Epidemiology from the Harvard School of Public Health.
Mike is the Chair of R&D, SAB Member and Board Director at Erasca. In these roles, he will help advance Erasca’s drug discovery portfolio by providing strategic input on portfolio optimization and offering in-depth scientific assessments of Erasca’s R&D activities.
Mike is a pioneer drug discoverer and biotech leader. As one of the original fifteen employees at Agouron, a biotech based in San Diego, he built a team that developed protein-structure based design, a novel approach to drug discovery that is utilized globally by drug discovery teams today. In 1997, the Agouron team launched Viracept®, an HIV protease inhibitor that achieved the highest first year launch sales of any biotech product at the time. His leadership at Agouron resulted in the discovery of multiple currently marketed anti-cancer agents, including Xalkori® and Inlyta®, a drug that won the American Chemical Society’s Heroes of Chemistry Award in 2018.
In 2005, Mike was recruited to Genentech to expand the organization’s drug discovery capabilities to include small molecules. Focused on agility and pioneering science, Mike built a team-based organization that today produces more than 40% of Genentech’s development portfolio, including the marketed anti-cancer agents Erivedge® and Cotellic®.
In 2015, Mike was appointed Executive Vice President and Head of Genentech’s Research and Early Development (gRED) and a member of the Roche Corporate Executive Committee. In this role, he was responsible for all aspects of gRED innovation, drug discovery and development. Mike also focused on building a team-based culture empowered to clear the path to patients. Under his leadership, gRED teams discovered and developed successful medicines that include Venclexta® with AbbVie, the first BCL-2 inhibitor, and Polivy™, an antibody drug conjugate for the treatment of DLBCL. Pioneering molecules in clinical development include mosunetuzumab, a bispecific antibody targeting CD20, and GDC-9545, a next-generation estrogen receptor degrader. Mike retired from Genentech in July 2020, leaving a diversity of drug platform types that includes personalized therapeutic vaccines and cellular therapies.
Mike holds a B.S. in Chemistry from the University of California, Los Angeles, and a Ph.D. in synthetic organic chemistry from the California Institute of Technology, and was an American Cancer Society postdoctoral fellow at Columbia University.
Kevan is currently an Investigator of the Howard Hughes Medical Institute, Professor in the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco and Professor in the Department of Chemistry at the University of California at Berkeley.
Kevan received his B.A. in Chemistry from Reed College in 1986, his Ph.D. in organic chemistry at UC Berkeley with Professor Peter Schultz and carried out post-doctoral work in cellular immunology at Stanford University with Professor Chris Goodnow.
Kevan’s research group is focused on the discovery of new small molecule tools and drug candidates targeting protein/lipid kinases, GTPases, and RNA helicases. His laboratory utilizes the tools of synthetic organic chemistry, protein engineering, structural biology, biochemistry and cell biology. He was inducted into the National Academy of Sciences (2010), the National Academy of Medicine (2011), and the American Academy of Arts and Sciences (2011). He has commercialized discoveries from his laboratory through co-founding several biotechnology companies in addition to Erasca including Intellikine, Araxes, Wellspring Biosciences, Kura Oncology, eFFECTOR Therapeutics, Mitokinin, Revolution Medicines and Kumquat Biosciences.
Stephen is the Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and a member of the Department of Cancer Biology at the Dana Farber Cancer Institute.
Research by Dr. Blacklow’s team has advanced understanding of how signaling between different cells induces growth and changes in cell identity both in normal development and in cancer. His research on the Notch pathway has led to the development of new investigational therapies for hematologic malignancies such as T cell acute lymphocytic leukemia (ALL).
Of his many awards and professional affiliations, Stephen received the National Cancer Institute’s prestigious Outstanding Investigator Award in 2017 and was elected to the Association of American Physicians in 2018. Stephen also directed the MD-PhD Program in Basic and Translational Sciences at Harvard Medical School and has served on Advisory Committees for pre-clinical departments, graduate programs, and MD-PhD programs at several major research universities and institutions, including Stanford University, the University of Pennsylvania, and the Memorial Sloan Kettering Cancer Center.
Stephen earned his M.D. and Ph.D. from Harvard University in 1991. He completed his residency in Clinical Pathology at Brigham and Women’s Hospital and conducted his postdoctoral research at the Whitehead Institute with Dr. Peter S. Kim.
Karen is the Founder and Director of the Center for Developing Targeted Cancer Therapies at Dana-Farber/Brigham and Women’s Cancer Center and is a Professor of Medicine and Ludwig Investigator at Harvard Medical School. She brings more than 20 years of experience in deconstructing mechanisms that underlie RAS-driven cancers and using this insight to devise new therapeutic strategies for these recalcitrant malignancies. Through her efforts as the Scientific Director of the NF Therapeutic Consortium and beyond, her discoveries have served as the foundation for multiple clinical trials in nervous system, lung, and breast cancers. In addition to her scientific endeavors, she is the Associate Director of Planning at the Dana Farber/Harvard Cancer Center, where she plays a leadership role in developing new strategic initiatives.
Karen received her Ph.D. in genetics at the University of Pennsylvania and completed her post-doctoral training in cancer biology at MIT.
Ryan is the Director of the Gastrointestinal Cancer Center Program and the Scientific Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center. He is an Associate Professor of Medicine at Harvard Medical School.
Ryan received his A.B. from Princeton University, and his M.D./Ph.D. from Stanford University. He completed his residency in Internal Medicine at the Massachusetts General Hospital and his fellowship in Medical Oncology at the Dana Faber Cancer Institute and the Massachusetts General Hospital Cancer Center.
He directs a research laboratory focused on personalized cancer medicine: the development of therapeutic strategies that target the specific mutations driving individual patients’ tumors. His work focuses on understanding the molecular determinants of response or resistance to anti-cancer therapies. His laboratory is also studying new ways to utilize liquid biopsy, and specifically analysis of circulating tumor DNA, in the clinic to optimize how we deliver cancer care to individual patients. Dr. Corcoran is a member of the National Cancer Institute Colorectal Cancer Task Force and the Rectal Cancer Task Force, and an elected member of the American Society for Clinical Investigation (ASCI).
George has dedicated his career to translational research aimed at understanding and treating precisely-defined subsets of sarcomas and other cancers. He was instrumental in the development of imatinib as the first effective therapy for the oncogene-driven sarcoma known as gastrointestinal stromal tumor (GIST). His collaborative research efforts have contributed to U.S. FDA and worldwide regulatory approval of several other therapeutic agents, including sunitinib and regorafenib for GIST, as well as pazopanib, trabectedin, eribulin, tazemetostat, larotrectinib and entrectinib for other sarcomas. He also served on the Scientific Advisory Board for Plexxikon to develop the first mutant BRAF inhibitor, vemurafenib, as a mutation-targeted therapy for a subset of melanomas.
George received his A.B. from Harvard and M.D. from Stanford before residency at the University of Washington, Seattle and medical oncology fellowship at the Dana-Farber Cancer Institute and Harvard Medical School.
He serves on the Board of Directors of two public companies (Blueprint Medicines and Translate BIO), as well as the Chair of the AACR Science Policy and Government Affairs Committee. He is also a founding director of the annual AACR special workshop on Translational Cancer Research for the Basic Scientist, and he was the recipient of the ASCO 2020 David A. Karnofsky Memorial Award for his research contributions.
Pablo is a group leader at the Cancer Institute of University College London, where he is also Professor of Cell Signalling and Cancer Biology. He has a long track record of pioneering research on the RAS signalling field with several prominent contributions throughout the years towards our understanding of how RAS oncogenes drive uncontrolled proliferation and survival of cancer cells and how this knowledge can inform the design of better targeted therapies.
Mike is the Chair of R&D, SAB Member and Board Director at Erasca. In these roles, he will help advance Erasca’s drug discovery portfolio by providing strategic input on portfolio optimization and offering in-depth scientific assessments of Erasca’s R&D activities.
Mike is a pioneer drug discoverer and biotech leader. As one of the original fifteen employees at Agouron, a biotech based in San Diego, he built a team that developed protein-structure based design, a novel approach to drug discovery that is utilized globally by drug discovery teams today. In 1997, the Agouron team launched Viracept®, an HIV protease inhibitor that achieved the highest first year launch sales of any biotech product at the time. His leadership at Agouron resulted in the discovery of multiple currently marketed anti-cancer agents, including Xalkori® and Inlyta®, a drug that won the American Chemical Society’s Heroes of Chemistry Award in 2018.
In 2005, Mike was recruited to Genentech to expand the organization’s drug discovery capabilities to include small molecules. Focused on agility and pioneering science, Mike built a team-based organization that today produces more than 40% of Genentech’s development portfolio, including the marketed anti-cancer agents Erivedge® and Cotellic®.
In 2015, Mike was appointed Executive Vice President and Head of Genentech’s Research and Early Development (gRED) and a member of the Roche Corporate Executive Committee. In this role, he was responsible for all aspects of gRED innovation, drug discovery and development. Mike also focused on building a team-based culture empowered to clear the path to patients. Under his leadership, gRED teams discovered and developed successful medicines that include Venclexta® with AbbVie, the first BCL-2 inhibitor, and Polivy™, an antibody drug conjugate for the treatment of DLBCL. Pioneering molecules in clinical development include mosunetuzumab, a bispecific antibody targeting CD20, and GDC-9545, a next-generation estrogen receptor degrader. Mike retired from Genentech in July 2020, leaving a diversity of drug platform types that includes personalized therapeutic vaccines and cellular therapies.
Mike holds a B.S. in Chemistry from the University of California, Los Angeles, and a Ph.D. in synthetic organic chemistry from the California Institute of Technology, and was an American Cancer Society postdoctoral fellow at Columbia University.
Senior Chemistry Advisor
Senior Chemistry Advisor
Bruce is Founder and Principal at Roth Pharma Consulting LLC and brings more than 30 years of experience in drug discovery and development. He is best known as the inventor of Lipitor®, for which he has received numerous awards, including the 2013 Perkin Medal, the highest award given to industrial chemists in the United States. Bruce has held key positions at Genentech, including Senior Vice President of Research and Early Development of Small Molecule Drug Discovery and both Vice President and Senior Director of Discovery Chemistry. At Genentech, he was named as one of the American Chemical Society Heroes in Chemistry for the discovery and development of Lipitor®. Prior to Genentech, Bruce served as Vice President of Chemistry at the Pfizer Global Research and Development, Ann Arbor Laboratories. He also served as an adjunct associate professor in the Department of Medicinal Chemistry in the School of Pharmacy of the University of Michigan. Bruce is the inventor or co-inventor of 54 issued U.S. patents and the author or co-author of 51 manuscripts, 35 published abstracts, 9 book chapters and review articles and has given more than 30 invited lectures. In 2013, he was inducted into the ACS Medicinal Chemistry Division Hall of Fame and in 2015 received the National Academy of Sciences Award for Chemistry in Service of Society.
Senior Crystallography Advisor
Senior Crystallography Advisor
Dave currently chairs the Scientific Advisory Committee and acts as one of a three-member Executive Committee involved in day-to-day grant and project operational decisions for the Bill and Melinda Gates Foundation supported “Structure guided Drug Discovery Consortium for Tuberculosis and Malaria.” He also served on the Medicines for Malaria Venture (MMV) Expert Scientific Advisory Committee where he also mentored several MMV supported drug discovery projects in which x-ray structures of the therapeutic target protein were used to inform medicinal chemistry. In 1985 he became the scientific founder of Agouron Pharmaceuticals, a company that pioneered the use of protein structure to inform medicinal chemistry for drug discovery. Agouron discovered, developed, and commercialized Viracept, the leading first-generation HIV protease targeted drug for treating AIDS. Agouron was acquired by Pfizer, Inc. in 2000. Three other drugs discovered at Agouron prior to the Pfizer acquisition subsequently gained FDA approval. Prior to Agouron, Dave served as the lead researcher and first author on the Science magazine publication that described the first three-dimensional x-ray structure of a drug (methotrexate) bound to its biological target (dihydrofolate reductase). He began his career at the University of California, San Diego, where he spent 15 years carrying out research on protein structure, enzyme mechanism of action, and the stereochemical basis of inhibitor and drug binding to proteins of chemotherapeutic interest.
Senior Development Advisor
Senior Development Advisor
Bringing over 20 years of experience as a senior leader in the pharmaceutical industry, most recently as Vice President of Genentech Research and Early Development, Greg is currently Owner and Principal of Cosma Biopharma Consulting, LLC. Greg has led efforts across R&D that have resulted in numerous approvals of currently marketed drugs, spanning diverse therapeutic areas and modalities. In addition to his broad development responsibilities at Genentech, Greg led Project Agility, an organization-wide effort to enhance innovation and pipeline delivery. He is widely considered as a trusted and transformative thought leader in the industry, applying disruptive strategies to enhance and accelerate pipeline delivery and efficiency. Prior to his career in biopharma, Greg was a faculty member at New York University Medical Center and Colorado State University.
Senior ADME/PK Advisor
Senior ADME/PK Advisor
Paul is President of Pearson Pharma Partners where he serves biotechnology and pharmaceutical companies and the National Institutes of Health in the areas of drug discovery, pharmacokinetics, drug metabolism, clinical pharmacology and drug interactions. Previously, he served as Global Head of Pharmacokinetics and Drug Metabolism at Amgen, the world’s largest biotechnology company. Prior to that, Paul served as Executive Director of Preclinical Drug Metabolism at Merck Research Laboratories. He has also held key positions at the Upjohn Company and has made major contributions to approvals of therapeutic agents to treat cancer and infectious diseases. Paul is the editor of the Handbook of Drug Metabolism (2019) and has published extensively in the field.
Paul received his Pharmacy degree and Ph.D. in Pharmaceutical Sciences from Aston University, England, and completed post-doctoral training at the University of Washington. Paul is actively engaged in the discovery and development of new human therapeutics in the fields of oncology and neuroscience to make a dramatic difference to the lives of patients.
Senior Toxicology Advisor
Senior Toxicology Advisor
Jane is the sole proprietor of JC Reg Tox where she consults for small biotech companies developing drugs that save or improve quality of life in patients. She brings more than 40 years of hands-on experience and proven records in basic research, study directing and monitoring, reporting and publishing, teamwork and leadership in product development, as well as regulatory requirements, submissions and interactions with regulatory agencies. She has held multiple key positions at Wyeth and AstraZeneca, where she was the toxicology project leader for an approved biologic oncology drug and an inhaled small molecule combination drug. Jane also contributed to the registrational approval of a gout drug by Ardea. Prior to joining the pharmaceutical industry, Jane worked as a research toxicologist in the personal care and crop protection industries after completing postdoctoral training in inhalation toxicology at Chemical Industry Institute of Toxicology (CIIT).
Jane received her Ph.D. in Environmental Toxicology from the Johns Hopkins School of Hygiene and Public Health. Jane has been a full member of the Society of Toxicology since 1985 and a member of the American Board of Toxicology since 1990.
Senior Medical Advisor
Senior Medical Advisor
James is a veteran biotech executive and consultant with more than 20 years of experience leading clinical development teams, designing oncology drug development and regulatory strategies, and conducting clinical trials. He has held senior roles in large and small pharmaceutical companies and has co-founded multiple biotechnology startups. After acting as a Consultant Chief Medical Officer, he joined the Board of Directors for Ignyta where he served until its acquisition by Roche in 2018. James was formerly the Chief Medical Officer and Senior Vice President, Drug Development and a member of the Board of Directors at Anadys Pharmaceuticals, which was acquired by Roche in 2011. Prior to joining Anadys Pharmaceuticals, he served at Pfizer, holding the positions of Vice President, Clinical Site Head, and Development Site Head and, prior to that, Executive Director and leader of Oncology Clinical Development. Prior to Pfizer, he held a variety of senior management positions at Wyeth-Ayerst Research, in the oncology, infectious diseases, and transplantation immunology therapeutic areas. He has also served as a member of the Board of Directors for InfuSystems, Inc., a public healthcare products and services company.
James received an M.D. degree from the University of North Carolina, Chapel Hill; completed his residency training at University of California, San Diego; and returned to Chapel Hill for his fellowship training in gynecologic oncology.
Senior Regulatory Affairs Advisor
Senior Regulatory Affairs Advisor
Linda is a Principal at Vincere Consulting, LLC, providing strategic expertise in international biologic and small molecule drug development, including personalized medicine. She has more than 20 years of management experience in regulatory affairs in large global pharmaceutical companies, small biotechnology companies and startups. Her career has been based on the development of science-based, innovative regulatory approaches to facilitate development of treatments for serious, life-threatening diseases across a variety of therapeutic areas. Linda embarked on consulting after serving as the Vice President of Regulatory Affairs at Ignyta until its acquisition by Roche in 2018. During her tenure at Ignyta, she successfully led global expedited regulatory designations for entrectinib in patients with NTRK fusion-positive tumors, expanding from the existing U.S. Breakthrough Therapy Designation to include the EU PRIME Scheme and the Japanese Strategy of Sakigake. Prior to Ignyta, she served as Vice President of Regulatory Affairs and Quality Assurance at Intercept Pharmaceuticals where she led the EU and US approval of Ocaliva® for treatment of Primary Biliary Cholangitis, a rare, life-threatening liver disease. Prior to this, she was a key member of the leadership team at a series of biotechnology companies developing personalized therapies to treat cancer. She served as Vice President of Regulatory Affairs and Quality Assurance at Ambit Biosciences and was a founder of Kanisa Pharmaceuticals. She also served as Director, Regulatory Affairs at Biogen IDEC, Inc. and its predecessor company, IDEC Pharmaceuticals, with responsibilities for a variety of products including Rituxan® for the treatment of non-Hodgkin’s lymphoma. Linda began her career in industry at Roche, where she held various senior regulatory affairs positions supporting CNS, oncology, antiviral and immunology products at Palo Alto, California and Nutley, New Jersey and led the U.S. approval of Tamiflu® for the treatment of influenza. Linda received her Ph.D. in neurobiology from Northwestern University followed by additional post-doctoral training in molecular biology from the Roche Institute of Molecular Biology.
Linda received a B.A. in biology from Lewis and Clark College where she is currently a member of the Board of Trustees and serves on the Advisory Board for the Bates Center for Entrepreneurship.
Senior Commercial Advisor
Senior Commercial Advisor
John brings over 20 years of biopharmaceutical commercial expertise, including significant commercial experience across business development, launch, and lifecycle management. He has led multiple global strategic teams in hematology and oncology at AstraZeneca, Celgene, and Bristol-Myers Squibb. Recently, as senior vice president of worldwide hematology at Bristol-Myers Squibb, he led the launch of five global hematology products including two cell therapies, Breyanzi® and Abecma®, overseeing a global portfolio of $15 billion in sales. At AstraZeneca, John led the strategic and global commercial function in oncology, establishing the strategy for multiple disease areas and leading 18 indication launches across the globe, including launching Tagrisso® globally, beating industry benchmarks with first year sales and doubling its sales potential, as well as launching Imfinzi® in stage 3 lung cancer to help establish a leading lung cancer franchise in targeted and immuno-oncology based therapies at the company. He also had increasing levels of responsibility at Novartis Oncology, most recently as vice president of the hematology franchise, ad interim, in the United States, where he successfully helped drive double-digit growth for a $3 billion franchise while preparing the organization for launches and integration. He has also advised early stage biotechnology companies on strategic, portfolio, and early commercialization decisions. Prior to his career in biopharmaceuticals, John was an associate principal at McKinsey & Company.
John earned a Ph.D. in biology from the Massachusetts Institute of Technology (MIT) and holds a B.S. in biochemistry from the University of Illinois Urbana-Champaign.
Chairman, CEO and Co-founder
Jonathan is Chairman and CEO of Erasca, which he co-founded in July 2018 with a mission to erase cancer. He is a physician-turned-venturepreneur at City Hill and ARCH Venture who founds, funds and leads mission-driven for-profit and non-profit ventures. He has served as Chairman and/or CEO and founding investor of six biotechnology companies that have collectively achieved global regulatory approval and launch of seven therapeutic products in oncology, immunology and drug delivery, benefitting thousands of patients worldwide, while generating approximately $10 billion of shareholder value. Jonathan has pioneered transformative advancements in drug delivery and precision oncology.
In drug delivery, he designed and executed landmark deals for Halozyme’s ENHANZE® drug delivery technology with Roche/Genentech and Baxter that formed the foundational business model and template for the company’s ten global alliances and five approved ENHANZE products that have enabled Halozyme to turn EBITDA positive and guide to $1 billion in royalty revenue in 2027. In precision oncology, Jonathan led Ignyta’s trailblazing pursuit of a global tissue agnostic label to transform cancer treatment with ROZLYTREK® (entrectinib) that, in the process of securing global regulatory approvals, became the first drug in biopharmaceutical history to achieve the unprecedented triple crown of breakthrough designations with BTD (FDA), PRIME (EMA) and Sakigake (PMDA). He led the strategic process that successfully resulted in the acquisition of Ignyta to become a key personalized healthcare pillar for Roche/Genentech, the leading precision oncology company in the world. He is continuing to pursue new frontiers of precision oncology at Erasca.